Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Schroeder, Mark A.; Choi, Jaebok; Atluri, Himachandana; Atkins, Jordan; Harding, Melinda; Eisele, Jeremy; Gao, Feng; Abboud, Ramzi; Abboud, Camille N.; Cashen, Amanda F.; Christopher, Matthew; Fehniger, Todd A.; Ferraro, Francesca; Ghobadi, Armin; Jacoby, Meagan A.; Pusic, Iskra; Stockerl‐Goldstein, Keith; Uy, Brian; Vij, Ravi; Walter, Matthew J.; Westervelt, Peter; DiPersio, John F.

doi:10.1182/blood-2022-157214

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were no events of primary graft failure. With low incidence of aGVHD on baricitinib therapy, further investigation is in progress to more fully evaluate the efficacy of baricitinib in GVHD prophylaxis ( 96 ).…”

Section: Jak Inhibitors For Gvhd Prophylaxismentioning

confidence: 99%

Janus kinase inhibition in the treatment and prevention of graft-versus-host disease

De Togni,

Cole,

Abboud

2024

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). For many years, corticosteroids have been the mainstay treatment for GVHD, but cases of steroid-refractory GVHD and the severe adverse effects of high-dose corticosteroids have increased the need for preventative and therapeutic strategies for GVHD. Due to the nature of alloreactive T cells, GVHD is inherently linked to the graft-versus-leukemia (GVL) effect, the therapeutic driving force behind stem cell transplantation. A considerable clinical challenge is to preserve GVL while suppressing GVHD. The field of GVHD research has greatly expanded over the past decades, including advancements in T cell modulation and depletion, antibody therapies, chemotherapeutics, cellular therapies, and Janus kinase inhibition. In this review, we discuss current approaches and advances in the prophylaxis and treatment of GVHD with a focus on new emerging advancements in Janus kinase inhibitor therapy.

show abstract

Section: Jak Inhibitors For Gvhd Prophylaxismentioning

confidence: 99%